Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016
Executive Summary
A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.
You may also be interested in...
Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza
Neurocrine secured FDA approval for the first drug to treat tardive dyskinesia, a large market that crosses multiple diseases and has blockbuster potential.
Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
The latest drug development news and highlights from our US FDA Performance Tracker.
Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia
Company no longer has to worry about a US FDA advisory committee review, which the agency cancelled. Launch preparations include hiring 140 sales reps.